Investor Relations
Company Overview
Avalo (AVTX) is a clinical stage biotechnology company focused on the treatment of immune mediated inflammatory diseases. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases.
Latest News
Apr 30, 2025 • 7:00 AM EDT
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference
Mar 26, 2025 • 7:00 AM EDT
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
Mar 20, 2025 • 7:00 AM EDT
Avalo Reports 2024 Financial Results and Recent Business Updates
Stock Information
Nasdaq: AVTX
Avalo Therapeutics, Inc.
Price
Change
Volume
Day Range
52 Week Range